A Randomized, Multicenter, Controlled Study to Compare Perioperative Chemotherapy of Oxaliplatin Combined with Ts-1 (sox) Versus Sox or Oxaliplatin with Capecitabine (xelox) As Post-Operative Chemotherapy in Locally Advanced Gastric Adenocarcinoma with D2 Dissection (resolve Trial)
Jiafu Ji,Lin Shen,Han Liang,Yingwei Xue,Xiaotian Zhang,Yanong Wang,Zhiwei Zhou,Yian Du,Wang Xinbao,Guoli Li,Jiren Yu,Dan Wu,Li Chen,Gang Xiao,Yulong He,Chengxue Dang,Zhongtao Zhang,Yanbing Zhou,Yihong Sun,Yong Li
DOI: https://doi.org/10.1200/jco.2016.34.15_suppl.tps4136
IF: 45.3
2016-01-01
Journal of Clinical Oncology
Abstract:TPS4136 Background: Perioperative treatment of locally advanced gastric cancer (LAGC) has always been argued by eastern and western scholars. MAGIC study has showed that peri-operative chemotherapy with 3 cycles of ECF has increased 13% on 5yOS compared with surgery alone; however, ACTS-GC or CLASSIC showed adjuvant chemotherapy after D2 dissection could achieve the similar survival benefit. So in this prospective randomized phase III study, we aims to compare the survival benefit as well as the safety for SOX(oxaliplatin/TS-1) as periopertative therapy versus SOX or XELOX as postoperative therapy after D2 dissection. Methods: RESOLVE Trial (ClinicalTrials.gov, NCT01534546) is a 3-arm, randomized, multi-center, open-label phase III trial. Primary endpoint is 3yDFS, and secondary endpoints include 5yOS, R0 resection rate and safety. Main eligibility criteria include gastric or gastro-esophageal junction adenocarcinoma, clinical stages cT4b/N+M0 or cT4aN+M0.Patients are randomized 1:1:1 with 2 strata: site and Lauren classification (diffuse or intestinal type).We anticipate that 3yDFS of perioperative chemotherapy of SOX is superior than postoperative XELOX, and 3y DFS of SOX is non-inferior to XELOX as adjuvant chemotherapy, α = 0.05, with power of 80%; number of subjects per treatment arm is 353,totally 1059. Arm A and Arm B will receive standard gastrectomy with D2 Lymphadenectomy first and 8 cycles of adjuvant XELOX or SOX later. [XELOX: capecitabine 1000 mg/m2, bid, d1~14 q3W; oxaliplatin 130mg/m2,d1, q3W; SOX: TS-1: 40~60mg bid,d1~14 q3W oxaliplatin F130mg/m2 d1,q3W]. Arm C will receive 3 cycles of neoadjuvant SOX first, and then standard gastrectomy with D2 lymphadenectomy, and 5 cycles of adjuvant SOX followed by 3 cycles of S-1 monotherapy. First patient entered into the study in Aug 2012. As of Dec 31, 2015, a total of 823 subjects were screened and 769 patients were recruited by 27 Chinese centers. Up to now, there were 251 patients are on treatment and 86 patients have died. Clinical trial information: NCT01534546.